Skip to main content

Press releases

2021-09-22
Moberg Pharma AB (OMX: MOB) today announces that it has received approval of the pediatric plan for MOB-015 from EMA’s paediatric committee (PDCO). This approval enables the company to pursue a full marketing authorization application providing up to ten years of exclusivity in Europe following approval. The company´s timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.
2021-08-10
REGISTRATION PREPARATIONS FULLY UNDERWAY
2021-08-03
STOCKHOLM, August 3[rd], 2021 – On August 10[th], 2021, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for January – June 2021. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2021-07-30
STOCKHOLM, July 30[th], 2021, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 45,511,425. The 910,000 newly issued shares are held by the company to secure its commitments under incentive programmes.
2021-06-23
STOCKHOLM, June 23[th], 2021, Moberg Pharma AB (OMX: MOB) announces the appointment of Agneta Larhed as Vice President Pharmaceutical Innovation & Development of Moberg Pharma. Dr Larhed will be joining the management team at Moberg Pharma in September.
2021-06-16
STOCKHOLM, June 16[th] 2021. Moberg Pharma AB (OMX: MOB) announced that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company’s commitments under incentive programme.
2021-06-10
STOCKHOLM, June 10[th] 2021. Moberg Pharma AB (OMX: MOB) announces that the results from the North American phase 3-study with MOB-015 (topical terbinafine) for the treatment of onychomycosis have been published in the Journal of the American Academy of Dermatology.
2021-05-18
STOCKHOLM, May 18[th], 2021. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2021-05-11
REGISTRATION PREPARATIONS FULLY UNDERWAY 
2021-05-04
STOCKHOLM, May 4[th], 2021 - On May 11[th], 2021, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for January – March 2021. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2021-04-19
Moberg Pharma´s Annual Report for July 2019 – December 2020 has been published and is available on www.mobergpharma.com
2021-04-19
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Tuesday, 18 May 2021.
2021-02-10
OncoZenge AB (publ) has today obtained approval from Nasdaq Stockholm for admission to trading on Nasdaq First North Growth Market. The first day of trading in OncoZenge's shares will be on Friday, February 12, 2021.
2021-02-09
Financing for both MOB-015 and BUPI
2021-02-08
In the prospectus published earlier today regarding OncoZenge AB’s (publ) rights issue and listing on Nasdaq First North Growth Market, it has been noted that the ISIN code for the share is incorrect. The correct ISIN code for the share is SE0015504097.
2021-02-08
OncoZenge AB (publ) has today obtained a conditional approval from Nasdaq Stockholm, containing customary conditions, regarding admission to trading on Nasdaq First North Growth Market. In addition, a prospectus regarding OncoZenge’s listing and its fully guaranteed rights issue of shares (the “Rights Issue”) has today been approved and registered by the Swedish Financial Supervisory Authority. The first day of trading in OncoZenge’s shares is expected to be February 12, 2021.
2021-02-02
STOCKHOLM, February 2[nd], 2021 - On February 9[th], 2021, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Year-end report for the financial year 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2021-01-29
On November 16, 2020, OncoZenge AB (publ), Moberg Pharma's subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market. Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021. The Board of OncoZenge has today, with the support of an authorization from an Extraordinary General Meeting on January 21, 2021, decided on the terms for the rights issue of approximately SEK 60 million (the “Rights Issue”). In addition, an indicative timetable for both the Rights Issue and the listing process on Nasdaq First North Growth Market is announced, where the first day of trading is expected to be on February 12, 2021.
2021-01-29
STOCKHOLM, January 29[th] 2021. During January 2021, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to the completion of the previously announced rights issue, and the final conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.
2021-01-14
Moberg Pharma AB (publ)’s (OMX: MOB) (“Moberg Pharma” or the “Company”) rights issue of units of approximately MSEK 150 (the “Rights Issue”) has now been registered with the Swedish Companies Registration Office. The last day of trading in paid subscribed units (“BTU”) is Monday January 18[th], 2021. The stop date at Euroclear for conversion of BTU to ordinary shares and warrants is Wednesday January 20[th], 2021.
2021-01-07
OncoZenge AB (publ), Moberg Pharma’s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge[®], currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032.